Healthcare Industry News: Paladin Labs
News Release - August 9, 2007
Paladin And Glide Pharma Sign Exclusive Agreement for Novel Needle-Free Drug Delivery SystemMONTREAL, CANADA--(Healthcare Sales & Marketing Network)--Aug 9, 2007 -- Paladin Labs Inc. (Toronto:PLB.TO ), a leading Canadian specialty pharmaceutical company, today announced that it has entered into an exclusive license and distribution agreement with Glide Pharmaceutical Technologies Limited (Glide Pharma(TM)) to develop and market Glide Pharma's innovative Glide SDI(TM) (Solid Dose Injector) needle-free drug delivery products in Canada. Under the terms of this agreement, Paladin will assume responsibility for local clinical trials, registration, marketing, sales and distribution of at least three of Glide Pharma's pipeline products which include: needle-free versions of sumatriptan, a leading migraine drug; octreotide, a peptide used in the treatment of acromegaly and neuroendocrine tumours; and, fentanyl, a widely-used pain medication used for breakthrough pain. According to IMS Canada, the combined markets for these three products exceeded $50 million in 2006.
"We are excited to be partnering with Paladin, a dynamic and creative company with a track record of successfully launching innovative pharmaceutical products in Canada," said Dr. Charles Potter, Chief Executive Officer of Glide Pharma. "The Glide SDI is ideally suited to the delivery of many drugs not only because of the simplicity of the device but also because of the enhanced stability and potential for controlled release of the drug when injected in a solid dosage form."
The two companies expect the first product under this agreement to be filed for Canadian regulatory approval in 2009. Financial terms of the agreement were not disclosed.
About the Glide SDI
The Glide SDI is an innovative needle-free injection system that allows the delivery of drugs, vaccines and other active pharmaceutical ingredients in a solid dosage form. The Glide actuator uses a spring mechanism to push solid drugs through the skin into the underlying tissue where they dissolve and are released into the patient's bloodstream. The device is simple to use, making it ideal for the self administration of drugs in the home environment. The system comprises a reusable, spring powered actuator and a pre-filled, disposable drug cassette. The used drug cassette can be disposed of with normal household waste and replaced with a fresh cassette holding the next dose. In the clinic, volunteers overwhelmingly stated that they preferred an injection with the Glide SDI to an injection with a standard needle and syringe.
Storing drugs in a solid dosage form typically makes them more stable and therefore refrigeration may not be essential, as is often the case with liquid formulations. The solid dosage form also enables immediate or controlled release of the drug into the blood stream, reducing the need for multiple injections. The Glide technology has the potential to generate substantial cost savings by eliminating the need to make arrangements for refrigerated storage of liquid drugs and for needle disposal - a major issue as 15 billion needles are used worldwide every year. It could also benefit patients with needle phobia and healthcare staff who suffer needle stick injuries, estimated at 600,000 to 800,000 annually, with the risk of HIV or Hepatitis infection.
About Glide Pharma
Glide Pharma is based near Oxford, UK. The Company, formerly known as Caretek Medical, was formed in 2001 and is focused on the commercialisation of the Glide SDI(TM) (Solid Dose Injector) for a range of drug and vaccine applications. Glide Pharma is developing a pipeline of both Glide-branded products and co-developed originator products based on its proprietary Glide SDI technology that allows the injection of drugs, vaccines and other active pharmaceutical ingredients in a solid dosage form.
For further information about Glide Pharma please visit the Company's web site at www.glidepharma.com.
About Paladin Labs Inc.
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Company's web site at www.paladinlabs.com.
This news release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Company's Annual Information Form for the year ended December 31, 2006. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly fillings, annual report and Annual Information Form and other fillings found on SEDAR at www.sedar.com.
Source: Paladin Labs
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.